Progenra, Inc.
Progenra is advancing a new class of medicine through Molecular Glues and targeted protein degradation. Their UbiPro™ platform leverages the ubiquitin system to develop therapies for challenging diseases, focusing on innovative modalities like PROTACs and Molecular Glues. They aim to redefine disease treatment by targeting the ubiquitin proteasome system and mitochondrial biology, with a focus on neurodegenerative, cardiovascular, and metabolic diseases. The company collaborates with academic institutions and industry partners to develop first-in-class therapeutics and is committed to transforming the standard of care for patients.
Industries
Nr. of Employees
small (1-50)
Progenra, Inc.
Products
PINK1 activators (discovery/preclinical)
Small-molecule activators of the PINK1 kinase designed to promote mitophagy and clearance of toxic protein aggregates; being evaluated for Parkinson’s disease and other neurodegenerative indications.
Parkin activators (research program)
Small-molecule activators of the Parkin E3 ligase developed to enhance Parkin-mediated mitophagy; program has received disease-focused foundation funding for development in Parkinson’s disease.
Molecular glue degraders for KRAS, IRAK4 and aggregated Tau (discovery-stage)
Discovery-stage molecular glue degraders targeting oncogenic and aggregated proteins identified in discovery efforts.
PROTAC candidates targeting RTKs and KRAS (preclinical)
PROTAC molecules generated using novel E3 ligase ligands to selectively degrade receptor tyrosine kinases and KRAS in preclinical studies.
PINK1 activators (discovery/preclinical)
Small-molecule activators of the PINK1 kinase designed to promote mitophagy and clearance of toxic protein aggregates; being evaluated for Parkinson’s disease and other neurodegenerative indications.
Parkin activators (research program)
Small-molecule activators of the Parkin E3 ligase developed to enhance Parkin-mediated mitophagy; program has received disease-focused foundation funding for development in Parkinson’s disease.
Molecular glue degraders for KRAS, IRAK4 and aggregated Tau (discovery-stage)
Discovery-stage molecular glue degraders targeting oncogenic and aggregated proteins identified in discovery efforts.
PROTAC candidates targeting RTKs and KRAS (preclinical)
PROTAC molecules generated using novel E3 ligase ligands to selectively degrade receptor tyrosine kinases and KRAS in preclinical studies.
Services
Licensing of discovery-stage molecular glue portfolio
Out-licensing opportunities for molecular glue activators and related discovery-stage assets to industry partners.
Collaborative discovery network (CROs + academics)
Collaborative research and CRO-mediated execution to supplement internal discovery and development activities.
Strategic development partnerships
Co-development and strategic collaborations to advance selected programs through preclinical development toward clinical candidate selection.
Business development and licensing inquiries
Business development engagement for partnership, licensing and funding opportunities.
Licensing of discovery-stage molecular glue portfolio
Out-licensing opportunities for molecular glue activators and related discovery-stage assets to industry partners.
Collaborative discovery network (CROs + academics)
Collaborative research and CRO-mediated execution to supplement internal discovery and development activities.
Strategic development partnerships
Co-development and strategic collaborations to advance selected programs through preclinical development toward clinical candidate selection.
Business development and licensing inquiries
Business development engagement for partnership, licensing and funding opportunities.
Expertise Areas
- Targeted protein degradation
- Mitochondrial biology and mitophagy
- Small-molecule medicinal chemistry
- Preclinical in vivo pharmacology
Key Technologies
- Molecular glues
- PROTACs (heterobifunctional degraders)
- PRESTACs (protein-rescue chimeras)
- E3 ligase ligand discovery